QUVIVIQ® (Daridorexant Hydrochloride Tablets) is an innovative dual orexin receptor antagonist (DORA) that overcomes the mechanistic limitations of traditional sedative-hypnotics. Since 2022, it has gained approval in multiple countries and regions including the United States, European Union, United Kingdom, Switzerland, Canada, Japan, and Hong Kong, China. In June 2025, driven by the collaboration between Simcere Pharmaceutical and Idorsia, it entered the Chinese market. As the only DORA-class drug approved by the European Medicines Agency (EMA) for improving daytime functioning, clinical trials confirm its rapid sleep induction, sustained sleep maintenance, significant improvement in daytime functioning, and favorable long-term safety profile. The approval of daridorexant in China offers a novel therapeutic option for insomnia patients, addressing unmet clinical needs unresolved by conventional sedative-hypnotics.